**Document No. 04b**

**Project title: NHS National Framework Agreement for the supply of Inhalation Anaesthetics and Vaporisers**

**Offer reference number: CM/PHR/24/5717**

**Period of framework agreement: 1st February 2025 to 31st January 2027, with an option or options to extend (at the discretion of the Authority) for a period or periods of up to 24 months**

**Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England**

**Assessment Criteria**

**Assessment criteria**

1. All medicines must conform to the fixed gateway criteria listed in Document No. 07b – Quality Assurance Policy to support the National Contract Procurement of Licensed Medicines v6 (October 2023), Appendix 1. Non-compliance on any single point will result in a Critical Score (refer to 3.3 Document No. 07b).

Medicine packaging should comply to best practice for labelling and packaging to ensure that medicines can be used safely by all patients, the public and healthcare professionals alike. Good practice principles set out in:

* + - * + Best practice guidance on the labelling and packaging of medicines (MHRA December 2020)
				+ Promoting safer use of injectable medicines (NPSA Alert 20, March 2007)
				+ Design for patient safety: A guide to the graphic design of medication packaging (NPSA 0463A 2008)
				+ Design for patient safety: A guide to labelling and packaging of injectable medicines (NPSA 2008) ISBN: 978-1-906624-02-6

If unacceptable patient safety risks are identified for which risk mitigation measures are likely to be impracticable or insufficiently effective a critical score will be assigned to the medicine.